This cost represents a discount of more than 85% to Humira (adalimumab), currently priced at $6,922 per carton of two pens.

Coherus BioSciences, Inc’s  YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors.

This cost represents a discount of more than 85% to Humira (adalimumab), currently priced at $6,922 per carton of two pens, Coherus reports.

YUSIMRY, approved in 2021 by the United States Food and Drug Administration, is a tumor necrosis factor blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

“Adalimumab products are important medicines for the treatment of serious autoimmune diseases, but cost is a barrier for many patients. With the launch of YUSIMRY, patients are now able to choose and access a high-quality, safe, and effective treatment at significant savings compared to Humira,” says Denny Lanfear, Coherus’ Chairman and Chief Executive Officer, in a news release.  “The price of Humira is nearly $90,000 a year today, putting this important therapy out of reach for many patients who are experiencing difficult financial health challenges. Our price for YUSIMRY of less than $13,000 a year was enabled by our investment in robust large-scale manufacturing, allowing us to be a high-volume, low-cost adalimumab biosimilar producer, ensuring reliable supply, and passing the savings directly to patients in need.”

YUSIMRY includes Coherus’ proprietary non-stinging, citrate-free formulation and a 29-gauge needle.  YUSIMRY Solutions- Coherus’ patient services platform – will ensure improved access as patients start or switch to YUSIMRY treatment based on a determination by their healthcare provider.